Acalnib (Acalabrutinib) 100 mg
Acalnib 100 mg is a next-generation targeted cancer therapy. Active ingredient: Acalabrutinib (100 mg).
Manufacturer: Hetero Healthcare (India). A generic version of the breakthrough drug Calquence.
Why switch to Acalabrutinib?
Unlike Ibrutinib, Acalnib is a highly selective BTK inhibitor. It binds specifically to the target without interfering with other kinases (like EGFR). This results in a much lower incidence of atrial fibrillation (heart rhythm issues) and bleeding events.
✅ Patient Profile: Ideal for patients who cannot tolerate Ibrutinib due to cardiovascular toxicity.
Approved for the treatment of adult patients with:
- Chronic Lymphocytic Leukemia (CLL): Treatment-naive or relapsed/refractory.
- Small Lymphocytic Lymphoma (SLL).
- Mantle Cell Lymphoma (MCL): Second-line therapy.
Dosage: 100 mg capsule taken twice daily (BID).
⚠️ CRITICAL ABSORPTION WARNING (Acid Dependency):
This drug needs stomach acid to work.
- 🚫 Do NOT take PPIs: Avoid Omeprazole, Esomeprazole, Lansoprazole. They reduce drug concentration significantly.
- ✅ Antacids: Take Acalnib at least 2 hours before taking calcium carbonate or other antacids.
- ✅ H2-blockers: Take Acalnib 2 hours before Famotidine/Ranitidine.
- Severe bleeding disorders.
- Upcoming surgery (Stop drug 3-7 days prior).
- Severe hepatic impairment.
- Pregnancy and breastfeeding.
- Concomitant use of Warfarin (increases bleeding risk).
Side effects are generally mild:
- Headache: A known "Acalabrutinib headache" often occurs early in treatment but usually resolves. Caffeine helps.
- Bruising: Minor subcutaneous bleeding (petechiae).
- Infections: Neutropenia (low white blood cell count).
- Diarrhea.
Similar products
What Customers Say
No reviews yet
Your review can be the first!